Abstract: The present invention relates to: a DNA aptamer specifically binding to culture filtrate 10 kDa (CFP10); a biosensor for diagnosing tuberculosis, comprising the same: and an information providing method for diagnosing tuberculosis. The present applicants have ascertained that the DNA aptamer, according to the present invention, has the ability to specifically bind to a CFP10 protein and that the binding strength thereof is strong. When the DNA aptamer of the present invention is used, excellent stability superior to that of ELISA methods using existing antibodies can be expected, and thus it is expected that the aptamer can be effectively used in the development of a composition for diagnosing tuberculosis, a biosensor for diagnosing tuberculosis, an information providing method for diagnosing tuberculosis, and the like.

Abstract: Provided is a method of diagnosing lymphoma by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal individual and subject-derived samples, wherein a lymphoma risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of lymphoma with proper cure, and after onset, early diagnosis may be performed, thereby reducing the incidence of lymphoma and increasing a therapeutic effect.

Abstract: The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from Akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet. In addition, in the present invention, a fermented food itself, prepared by adding Akkermansia muciniphila, can be used for the purpose of preventing or alleviating a metabolic disease occurring or exacerbated due to a high fat diet.

Abstract: The present invention relates to an extracellular vesicle derived from Lactobacillus paracasei and a use thereof, and more particularly, to a composition for alleviating, preventing or treating an inflammation disease and a cancer, which comprises an extracellular vesicle derived from Lactobacillus paracasei, which may effectively inhibit various inflammation disease, as an active ingredient, and the like.

Abstract: The present invention relates to a method of diagnosing ovarian cancer through microbial metagenomic analysis, and more particularly to a method of diagnosing ovarian cancer by analyzing an increase or decrease in content of specific bacteria or archaea-derived extracellular vesicles through metagenomic analysis using a subject-derived sample. Extracellular vesicles secreted from microorganisms existing in the environment are absorbed into the human body, and thus may directly affect the occurrence of cancer, and it is difficult to diagnose ovarian cancer early before symptoms thereof so that efficient treatment thereof is difficult.

Abstract: The present invention relates to a method of diagnosing atopic dermatitis through microbial metagenomic analysis, and more specifically, the present invention relates to a method of diagnosing atopic dermatitis by analyzing an increase or decrease in the content of specific bacteria- or archaea-derived extracellular vesicles by conducting a metagenome analysis using normal individual and subject-derived samples. Since the extracellular vesicles secreted from microorganisms present in the environment can be absorbed into the human body to regulate immune functions and directly affect the occurrence of inflammation. It is difficult to early diagnose atopic dermatitis before symptoms appear, and thus it is difficult to effectively treat the atopic dermatitis.

Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

Abstract: The present invention relates to a method for diagnosing lung cancer via bacterial metagenomic analysis and, more particularly, a method for diagnosing lung cancer by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria through bacterial metagenomic analysis using a subject-derived sample. An extracellular vesicle secreted from a bacterium present in the environment can be absorbed into the body and directly affect the occurrence of cancer, and lung cancer is difficult to diagnose early on before any symptom appears, which makes efficient treatment difficult.

Abstract: The present invention relates to a method of providing information for gastric cancer diagnosis through bacterial metagenomic analysis, more particularly, a method of predicting a risk for gastric cancer or diagnosing gastric cancer by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria through bacterial metagenomic analysis of genomes present in extracellular vesicles isolated from a subject-derived sample. Extracellular vesicles secreted from bacteria existing in the environment are absorbed into the human body, and thus may directly affect the occurrence of cancer, and gastric cancer has a very high incidence rate and a very high mortality rate in Korea, and thus prevention and early diagnosis thereof through prediction of the onset thereof is very important.

Abstract: The present invention relates to a method of diagnosing heart disease through bacterial metagenome analysis. More specifically, the present invention relates to a method of predicting the causative factor and onset of heart disease, diagnosing heart disease early, and predicting prognosis by analyzing the increase or decrease in the content of an extracellular vesicle derived from specific bacteria by performing bacterial metagenome analysis using a subject-derived sample. Through metagenome analysis of a bacteria-derived extracellular vesicle using a human body-derived sample according to the present invention, the risk of the onset of heart disease is predicted in advance, and thus a risk group for heart disease is diagnosed and predicted early. Accordingly, through suitable management, the moment of onset of disease can be performed even after the onset of disease. Therefore, the rate of onset of heart disease can be reduced, and the effect of treatment can be improved.

Abstract: The present invention relates to a method of diagnosing chronic obstructive airway disease such as asthma, COPD, and the like through bacterial metagenomic analysis, and more particularly, to a method of diagnosing chronic obstructive pulmonary disease and asthma by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria through bacterial metagenomic analysis using a subject-derived sample. Extracellular vesicles secreted from bacteria present in the environment are absorbed into the human body, and thus may directly affect inflammatory responses, and it is difficult to diagnose chronic obstructive airway diseases such as asthma, COPD, and the like early before symptoms occur, and thus efficient treatment therefor is difficult.

Abstract: The present invention relates to a method of diagnosing Parkinson's disease through bacterial metagenomic analysis, and more particularly, to a method of diagnosing Parkinson's disease by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria by bacterial metagenomic analysis using a subject-derived sample. Extracellular vesicles secreted from microorganisms such as bacteria, archaea, and the like present in the environment are absorbed into the human body and distributed in the brain, and thus may directly affect inflammatory responses and brain functions, and since it is difficult to implement early diagnosis for Parkinson's disease, which is characterized by inflammation, before symptoms appear, efficient treatment therefor is difficult.

Abstract: Provided is a composition for the treatment of pregnancy-associated diseases, and more particularly, to a pharmaceutical composition for the prevention or treatment of premature delivery or breast cancer. The pharmaceutical composition including extracellular vesicles derived from bacteria belonging to the genus Bacillus as an active ingredient may induce pregnancy or prevent premature delivery of pregnant women, may be used to prevent or treat pregnancy-associated diseases such as breast cancer, and may be used to diagnose a risk of premature delivery by measuring the amount of extracellular vesicles derived from bacteria belonging to the genus Bacillus in pregnant women.

Abstract: Provided are vesicles derived from bacteria belonging to the genus Cupriavidus, a composition and a use thereof, wherein the vesicles or composition may be usefully used for the purpose of developing a method of diagnosing a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, or depression.

Abstract: Provided are vesicles derived from bacteria belonging to the genus Micrococcus, a composition and a use thereof, wherein the vesicles and the composition comprising the same may be effectively used for the development of a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, chronic obstructive pulmonary disease (COPD), dementia, or diabetes.

Abstract: The present invention relates to vesicles derived from bacteria of the genus Propionibacterium and a use thereof. It was experimentally confirmed that the production of vesicles derived from bacteria of the genus Propionibacterium was increased in the body by a high-fat diet rather than a high-carbohydrate diet; the vesicles were significantly reduced in the blood of patients with cancers, such as breast cancer and liver cancer, inflammation diseases, such as asthma and atopic dermatitis, and metabolic diseases, such as diabetes and liver cirrhosis, compared with normal persons; and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, inhibited the apoptosis of keratinocytes, and increased the expression of an androgen receptor in the body.

Abstract: Provided are a method of predicting the onset and causative factors of colon tumors such as a colon polyp, colon cancer, and the like through metagenomic analysis of bacteria-derived extracellular vesicles present in a human body-derived substance, and a method of diagnosing causative factors and risk of colon tumors by sequencing of a metagenome present in bacteria-derived extracellular vesicles in stool or urine.

Abstract: Provided is a composition for preventing, ameliorating, or treating inflammatory diseases, the composition including, as active ingredients, lactic acid bacteria-derived extracellular vesicles isolated from culture fluid of lactic acid bacteria; and a method for diagnosing atopic dermatitis. The composition including the lactic acid bacteria-derived extracellular vesicles as active ingredients is expected to be usefully used in development of drugs, cosmetics, or health functional food for preventing, ameliorating, or treating inflammatory diseases such as atopic dermatitis, chronic rhinitis, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, sepsis, etc. Also, the composition will be usefully used for diagnosis of atopic dermatitis by measuring the distribution of lactic acid bacteria-derived extracellular vesicles in a urine or blood sample.

Abstract: The present invention relates to an immunomodulator for the prevention or treatment of an allergic disease caused by house dust mite-derived allergens. Particularly, the present invention provides an immunomodulatory pharmaceutical composition comprising as an effective ingredient a bacteria extracellular vesicle containing an allergens derived from North American house dust mite or European house dust mite, and a preparation method therefor.

Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cance